19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

Key Takeaways Explain This Topic AI

Acute Liver Failure (ALF) is clinically defined by the rapid onset of severe hepatocellular injury in a patient without pre-existing cirrhosis, characterized by coagulopathy (INR ≥1.5) and any degree of hepatic encephalopathy developing within 26 weeks of illness onset.

Acetaminophen toxicity is the leading etiology of ALF in North America (~50% of cases); the Rumack-Matthew nomogram guides therapy for single acute ingestions presenting 4 to 24 hours post-ingestion, and N-acetylcysteine (NAC) must be administered empirically without waiting for lab results if the ingestion occurred >8 hours prior, transaminases are elevated, or the ingestion time is unknown.

In ALF, routine prophylactic correction of an elevated INR with fresh frozen plasma (FFP) is strictly contraindicated because it obscures the single most sensitive prognostic marker of hepatic recovery; FFP and platelets are reserved exclusively for active severe bleeding or immediately prior to high-risk invasive procedures (e.g., ICP monitor insertion).

Acute cholangitis is a life-threatening biliary emergency resulting from ascending infection in an obstructed ductal tree; Reynolds' pentad (fever, RUQ pain, jaundice, septic shock, and altered mental status) indicates acute toxic suppurative cholangitis requiring emergent crystalloid resuscitation, broad-spectrum IV antibiotics (e.g., piperacillin-tazobactam), and urgent ERCP biliary decompression within 24 hours.

Severe jaundice is categorized by bilirubin fractionation: pre-hepatic jaundice manifests with unconjugated (indirect) hyperbilirubinemia, normal urine color, and hemolytic markers; intra-hepatic jaundice exhibits mixed hyperbilirubinemia with marked transaminase elevations; and post-hepatic (obstructive) jaundice exhibits conjugated (direct) hyperbilirubinemia (>50% of total), acholic pale clay-colored stools, dark tea-colored urine with positive urine bilirubin, and marked ALP/GGT elevations.

Last updated: September 2026

Acute Liver Failure (ALF / Fulminant Hepatic Failure)

Acute Liver Failure (ALF), historically designated fulminant hepatic failure, is a rare, devastating syndrome defined by the rapid onset of severe hepatocellular dysfunction with catastrophic systemic consequences.

Clinical Definition & The Diagnostic Triad

To fulfill the diagnostic definition of Acute Liver Failure, a patient must meet three core clinical criteria:

Severe Acute Hepatocellular Injury : Manifested by markedly elevated serum aminotransferases (AST and ALT, frequently in the thousands) and jaundice;

Absence of Pre-Existing Cirrhosis or Chronic Liver Disease : (Recognized exceptions include acute presentations of autoimmune hepatitis, Wilson disease, and vertically acquired acute hepatitis B virus infection);

The Hallmark Coagulopathy & Encephalopathy :

Coagulopathy : A prolonged prothrombin time yielding an INR ≥1.5 ;

Hepatic Encephalopathy : Any clinical degree of altered mental status, asterixis, or neuropsychiatric dysfunction developing within 26 weeks of initial symptom onset.

Chronological Classification of ALF

Based on the interval between the onset of jaundice and the appearance of hepatic encephalopathy, ALF is classified into three temporal phenotypes, which carry critical prognostic significance:

Hyperacute Liver Failure (<7 Days) :

Typical Etiologies : Acetaminophen overdose, ischemic hepatitis ("shock liver"), hepatitis A virus (HAV), and hepatitis E virus (HEV).

Clinical Characteristics : Massive transaminase surges (often >5,000–10,000 IU/L), severe coagulopathy, and early cerebral edema, but moderate jaundice .

Prognosis : Carries the highest rate of spontaneous hepatic regeneration and survival with medical management (~60%).

Acute Liver Failure (7 to 21 Days) :

Typical Etiologies : Acute hepatitis B virus (HBV) infection.

Prognosis : Intermediate spontaneous survival rate (~30–40%).

Subacute Liver Failure (3 to 26 Weeks) :

Typical Etiologies : Idiosyncratic drug-induced liver injury (DILI), autoimmune hepatitis, and indeterminate/cryptogenic causes.

Clinical Characteristics : Insidious, progressive, severe deep jaundice , mild-to-moderate transaminase elevations, and late encephalopathy.

Prognosis : Carries the worst prognosis ; spontaneous recovery is <15% to 20%, and emergent liver transplantation is usually required.

Etiological Spectrum of Acute Liver Failure ETIOLOGICAL SPECTRUM OF ACUTE LIVER FAILURE

• ┌─────────────────────────────────────────┐ ┌─────────────────────────────────────────┐
• │ ACETAMINOPHEN TOXICITY (~50%) │ │ IDIOSYNCRATIC DILI (~12%) │
• ├─────────────────────────────────────────┤ ├─────────────────────────────────────────┤
• │ • Leading cause of ALF in US & UK │ │ • Antimicrobials: INH, Augmentin, Bactrim│
• │ • NAPQI depletes glutathione │ │ • Antiepileptics: Valproate, Phenytoin │
• │ • Centrilobular (Zone 3) necrosis │ │ • Herbal supplements: Green tea, Kava │
• │ • Specific Antidote: N-ACETYLCYSTEINE │ │ • Poor spontaneous survival (<20%) │
• └─────────────────────────────────────────┘ └─────────────────────────────────────────┘
• ┌─────────────────────────────────────────┐ ┌─────────────────────────────────────────┐
• │ VIRAL HEPATITIS (~10%) │ │ ACUTE WILSON DISEASE (<2%) │
• ├─────────────────────────────────────────┤ ├─────────────────────────────────────────┤
• │ • HBV (± HDV superinfection / coinfect) │ │ • Coombs-negative hemolytic anemia │
• │ • HAV in older adults with liver disease│ │ • Alk Phos to Total Bilirubin ratio <4.0│
• │ • HEV: 20-25% mortality in PREGNANCY │ │ • Kayser-Fleischer rings on slit-lamp │
• │ • Herpes simplex (HSV) in immunocomp │ │ • 100% fatal without liver transplant │
• └─────────────────────────────────────────┘ └─────────────────────────────────────────┘
• ┌───────────────────────────────────────────────────────────────────────────────────────┐
• │ ISCHEMIC HEPATITIS ("SHOCK LIVER", ~5-10%) │
• ├───────────────────────────────────────────────────────────────────────────────────────┤
• │ • Transient severe hypotension, cardiac arrest, cardiogenic shock, or sepsis │
• │ • Precipitous surge in AST/ALT (>3,000 to >10,000 IU/L) alongside elevated LDH │
• │ • Rapid >50% transaminase decline within 48 to 72 hours of hemodynamic stabilization │
• └───────────────────────────────────────────────────────────────────────────────────────┘

Acetaminophen (APAP) Hepatotoxicity (~50% of ALF cases in North America) :

Normal Metabolism : At therapeutic doses (≤4 g/day in adults), 90% of acetaminophen is metabolized in hepatocytes via Phase II glucuronidation and sulfation into nontoxic, water-soluble conjugates excreted in urine. Approximately 5% to 10% is metabolized by cytochrome P450 CYP2E1 into N-acetyl-p-benzoquinone imine (NAPQI) , a highly reactive, toxic electrophile. Endogenous hepatic glutathione immediately binds NAPQI, forming nontoxic mercapturic acid and cysteine conjugates.

Mechanism of Toxicity : Massive acute ingestion (>7.5 to 10 g in adults, or >150 mg/kg) saturates glucuronidation and sulfation pathways, shifting APAP shunting to CYP2E1. When hepatic glutathione stores fall below 30% of normal baseline , NAPQI can no longer be detoxified. Free NAPQI covalently binds to cysteine sulfhydryl groups on hepatocyte mitochondrial proteins, inducing massive reactive oxygen species generation, opening of the mitochondrial permeability transition pore, loss of ATP synthesis, and extensive centrilobular (Zone 3) hepatic necrosis .

High-Risk Vulnerabilities : Chronic alcohol consumption (induces CYP2E1 activity), malnutrition/fasting (depletes baseline glutathione), and concurrent use of CYP-inducing medications (phenytoin, carbamazepine, rifampin) can precipitate catastrophic hepatotoxicity at supratherapeutic doses as low as 4 to 6 g/day .

Idiosyncratic Drug-Induced Liver Injury (DILI, ~12% of cases) :

Non-dose-dependent, unpredictable hepatotoxicity.

Common offending agents:

Antimicrobials : Isoniazid (INH; black box warning for severe/fatal hepatitis), Amoxicillin-clavulanate (Augmentin; most common cause of cholestatic/mixed DILI), Nitrofurantoin, Trimethoprim-sulfamethoxazole (TMP-SMX);

Antiepileptic Drugs : Valproic acid (microvesicular steatosis, hyperammonemic encephalopathy), Phenytoin, Carbamazepine;

Herbal and Dietary Supplements : Green tea extract (epigallocatechin gallate), Kava kava, Usnic acid, Black cohosh, anabolic steroids.

Viral Hepatitis (~10% of cases) :

Hepatitis B Virus (HBV) : The most frequent viral cause of ALF in North America and worldwide. Acute infection or spontaneous/immunosuppression-induced reactivation of chronic HBV. Coinfection or superinfection with Hepatitis D Virus (HDV) carries a markedly increased risk of fulminant hepatic necrosis.

Hepatitis A Virus (HAV) : Causes ALF in <0.5% of pediatric cases, but the risk surges to >2% to 3% in adults older than 50 years or those with underlying chronic liver disease.

Hepatitis E Virus (HEV) : Fecal-oral, waterborne transmission (endemic to South/East Asia and Africa). Carries a catastrophic 20% to 25% mortality rate with fulminant hepatic failure in pregnant females during the second and third trimesters.

Herpes Simplex Virus (HSV) : Rare but treatable etiology in pregnant women or immunocompromised hosts; presents with high fever, anicteric hepatitis (markedly elevated transaminases with relatively normal bilirubin), and leukopenia; requires immediate high-dose IV acyclovir.

Acute Wilson Disease (<2% of cases) :

Rare, autosomal recessive disorder of biliary copper excretion ( ATP7B gene mutation) presenting in children and young adults as hyperacute liver failure.

Cardinal Diagnostic Hallmarks :

Severe Coombs-negative microangiopathic hemolytic anemia (caused by massive release of toxic free copper into the bloodstream lysing erythrocyte membranes);

• Markedly low Alkaline Phosphatase to Total Bilirubin ratio (<4.0, or <2.0) ;
• Low serum ceruloplasmin and elevated 24-hour urinary copper excretion;

Presence of Kayser-Fleischer rings on slit-lamp ophthalmologic examination (seen in ~50% of acute hepatic presentations);

Untreated acute Wilsonian liver failure carries a 100% mortality rate without emergency liver transplantation .

Ischemic Hepatitis ("Shock Liver", ~5–10% of cases) :

Triggered by transient, profound systemic hypotension, cardiac arrest, cardiogenic shock, or severe sepsis.

Biochemical Profile : Characterized by a precipitous, explosive surge in serum AST and ALT ( frequently >3,000 to >10,000 IU/L ) occurring within 24 hours of the hypotensive insult, accompanied by dramatic elevations in serum lactate dehydrogenase (LDH; AST/LDH ratio typically <1.5).

Following hemodynamic stabilization and restoration of cardiac output, transaminases decline rapidly by >50% per day, normalizing within 7 to 10 days.

Acute Budd-Chiari Syndrome :

Acute thrombotic occlusion of the major hepatic veins or inferior vena cava, frequently associated with underlying myeloproliferative disorders ( JAK2 V617F mutation, polycythemia vera) or antiphospholipid syndrome. Presents with painful tender hepatomegaly, rapid-onset intractable ascites, and liver failure; Doppler ultrasound confirms absent hepatic venous flow.

Pregnancy-Specific Hepatic Emergencies :

Acute Fatty Liver of Pregnancy (AFLP) : Occurs in the third trimester (Swansea diagnostic criteria: microvesicular steatosis, hypoglycemia, hyperuricemia, renal dysfunction; linked to fetal homozygous deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase [LCHAD]). Mandates immediate emergent delivery of the fetus.

HELLP Syndrome : Severe preeclampsia variant characterized by Hemolysis, Elevated Liver enzymes, and Low Platelets.

• Acetaminophen Toxicity Protocols & N-Acetylcysteine (NAC)
• The Rumack-Matthew Nomogram RUMACK-MATTHEW NOMOGRAM FOR ACETAMINOPHEN TOXICITY

• APAP (mcg/mL)
• 500 ┼
• │ ● (Peak absorption)
• 200 ┼
• 150 ┼───────────────────* (Treatment Line: 150 mcg/mL at 4 Hours)
• │ \
• 100 ┼ \
• │ \
• 50 ┼ \───────* (Treatment Line: 37.5 mcg/mL at 12 Hours)
• │ \
• │ NO TOXICITY ZONE \───────* (4.7 mcg/mL at 24 Hours)
• 0 ┴─────┬─────┬─────┬─────┬─────┬─────┬─────┬─────┬─────┬─────┬
• 0 4 6 8 10 12 14 16 18 20 24
• Hours Post-Acute Ingestion

Strict Scope of Use : Validated exclusively for a single acute ingestion of known timing presenting between 4 and 24 hours post-ingestion.

Interpretation : Obtain a serum acetaminophen concentration at or after 4 hours post-ingestion. If the plotted level falls on or above the "treatment line" (which starts at 150 mcg/mL at 4 hours and declines logarithmically to 37.5 mcg/mL at 12 hours ), antidote therapy is mandatory.

Nomogram Inapplicability : The nomogram CANNOT be used to evaluate chronic supratherapeutic ingestions, repeated doses over time, ingestions occurring >24 hours prior, or extended-release APAP formulations (which require serial levels 4 to 6 hours apart).

N-Acetylcysteine (NAC): Mechanisms & Clinical Protocols

Pharmacologic Mechanisms :

Serves as a direct precursor for the synthesis of intracellular glutathione, replenishing depleted hepatic glutathione stores;

• Binds and detoxifies free NAPQI directly as a glutathione surrogate;
• Provides sulfhydryl groups for sulfate conjugation pathways;

Acts as a potent antioxidant, improves hepatic microcirculatory blood flow, enhances systemic oxygen delivery, and suppresses cerebral edema in established liver failure.

The Critical 8-Hour Window :

When administered within 8 hours of acute ingestion, NAC provides nearly 100% complete protection against severe hepatotoxicity and death .

Beyond 8 hours, efficacy progressively declines, but NAC must still be administered at any time point post-ingestion , even days later, as it has been conclusively proven to reduce mortality, cerebral edema, and the need for liver transplantation in established ALF.

Important

THE EMPIRIC NAC RULE FOR LATE PRESENTATIONS (>8 HOURS): If a patient presents >8 hours after an acute ingestion , or if the time of ingestion is unknown, or if serum transaminases are already elevated, administer the intravenous loading dose of NAC IMMEDIATELY . Do NOT delay antidote administration to wait for laboratory results. If the subsequent 4-hour APAP level falls below the nomogram treatment line and transaminases are normal, NAC can be safely discontinued.

Dosing Protocols for N-Acetylcysteine

Intravenous 3-Bag Protocol (Total 300 mg/kg over 21 Hours) :

Bag 1 (Loading Dose) : 150 mg/kg IV in 200 mL 5% Dextrose (D5W) infused over 60 minutes .

Bag 2 : 50 mg/kg IV in 500 mL D5W infused over 4 hours .

Bag 3 : 100 mg/kg IV in 1,000 mL D5W infused over 16 hours .

Continuation Rule : At the conclusion of Bag 3, recheck serum APAP, transaminases, and INR. If APAP is detectable, transaminases remain elevated, or INR >1.5, continue the third-bag infusion rate (6.25 mg/kg/hour or 100 mg/kg over 16 hours) continuously until transaminases are clearly declining and INR is <1.5.

Adverse Effects : Anaphylactoid reactions (flushing, urticaria, bronchospasm, angioedema) occur in up to 10% to 15% of IV infusions due to non-IgE-mediated histamine release; managed by temporarily pausing the infusion, administering antihistamines (diphenhydramine), and resuming the infusion at a slower rate.

Oral 72-Hour Protocol :

Loading dose of 140 mg/kg PO , followed by 70 mg/kg PO every 4 hours for 17 additional maintenance doses (total 1,330 mg/kg over 72 hours). Diluted in juice or soda; repeat dose if vomited within 1 hour.

• Critical Care Complications of Acute Liver Failure
• 1. Cerebral Edema & Intracranial Hypertension (ICH)

Cerebral edema leading to uncal/transtentorial herniation and brainstem death is the leading cause of mortality in hyperacute liver failure.

Pathophysiology : Severe hepatic dysfunction impairs the urea cycle, causing massive systemic arterial hyperammonemia (>150–200 µmol/L) . Circulating ammonia readily crosses the blood-brain barrier into cerebral astrocytes, where glutamine synthetase converts ammonia and glutamate into glutamine . Intracellular accumulation of glutamine exerts a potent osmotic driving force, drawing water into astrocytes, producing cytotoxic astrocyte swelling, cerebral edema, loss of cerebral autoregulation, and intracranial hypertension (intracranial pressure [ICP] >20 mm Hg).

Critical Management Strategy :

Elevate head of bed to 30 degrees ; maintain neutral neck alignment to maximize cerebral venous drainage;

Elective Endotracheal Intubation : Mandatory for West Haven Grade III or IV encephalopathy to protect the airway and facilitate neuro-monitoring;

Target Serum Sodium 145 to 150 mEq/L : Infuse hypertonic 3% sodium chloride to induce mild systemic hypernatremia, creating an osmotic gradient that extracts water from edematous brain parenchyma;

Intravenous Mannitol (0.5 to 1.0 g/kg IV bolus) : Indicated for acute surges in ICP >20 mm Hg or signs of impending cerebral herniation (sluggish/dilated pupils, decerebrate posturing, Cushing triad);

Clinical Pearl : Lactulose and rifaximin, while standard in chronic cirrhotic encephalopathy, have no proven benefit in hyperacute ALF and can cause severe bowel distension that physically impedes emergent liver transplantation.

2. "Rebalanced Hemostasis" & Coagulopathy Management

The True Physiology : The failing liver loses the capacity to synthesize vitamin K-dependent procoagulant clotting factors (II, VII, IX, X, V), causing marked prolongation of the prothrombin time and elevation of the INR. However, hepatocytes concurrently lose the ability to synthesize endogenous anticoagulant proteins (Protein C, Protein S, and Antithrombin III) . Consequently, patients with ALF exist in a fragile state of rebalanced hemostasis and are at equal risk for venous thromboembolism and hemorrhage.

The Absolute FFP Transfusion Rule :

Routine prophylactic transfusion of Fresh Frozen Plasma (FFP) to "correct" an elevated INR in the absence of active bleeding is STRICTLY CONTRAINDICATED .

FFP infusion fails to reduce clinical bleeding risks, induces circulatory volume overload, and catastrophically erases the INR—the single most sensitive, dynamic prognostic indicator of hepatic recovery or deterioration .

FFP and platelets should be transfused ONLY for active, clinically overt bleeding or immediately prior to high-risk invasive procedures (such as placement of an intracranial pressure monitoring bolt).

3. Metabolic & Infectious Derangements

Hypoglycemia : Loss of hepatic glycogen stores and impaired gluconeogenesis; requires continuous capillary blood glucose monitoring every 1 to 2 hours and continuous infusion of 10% or 20% dextrose.

Severe Bacterial & Fungal Sepsis : Impaired reticuloendothelial clearance, complement deficiency, and neutrophil dysfunction; maintain a low threshold for broad-spectrum empiric IV antimicrobials.

King's College Criteria for Emergent Liver Transplantation in ALF

The King's College Hospital Criteria represent the most widely validated prognostic model worldwide, identifying patients with acute liver failure who have a >80% to 90% predicted in-hospital mortality without emergency orthotopic liver transplantation:

1. Acetaminophen-Induced Acute Liver Failure

Emergency liver transplantation is indicated if the patient meets EITHER of the following criteria:

Arterial Blood pH <7.30 measured after adequate volume resuscitation (regardless of the grade of encephalopathy);

OR ALL THREE of the following concurrent criteria (regardless of arterial pH):

• Prothrombin time >100 seconds (INR >6.5) ;
• Serum Creatinine >3.4 mg/dL (>300 µmol/L) ;

West Haven Grade III or IV Hepatic Encephalopathy .

2. Non-Acetaminophen Acute Liver Failure

Emergency liver transplantation is indicated if the patient meets EITHER of the following criteria:

Prothrombin time >100 seconds (INR >6.5) (regardless of encephalopathy grade);

OR ANY THREE of the following five unfavorable prognostic factors :

• Etiology : Idiosyncratic drug toxicity (DILI) or indeterminate/cryptogenic cause;
• Age : <10 years or >40 years;
• Duration of Jaundice : Jaundice to encephalopathy interval >7 days;
• Prothrombin Time : >50 seconds (INR >3.5);

Serum Total Bilirubin : >17.5 mg/dL (>300 µmol/L).

Acute Ascending Cholangitis: Pathogenesis, Microbiology & Urgent Decompression

Acute cholangitis is a life-threatening systemic infection of the biliary tree carrying a high mortality if untreated.

Pathophysiology & "Cholo-Venous Reflux"

Development of acute cholangitis requires two concurrent pathophysiologic prerequisites:

Mechanical Obstruction of the Biliary Tree : Caused by choledocholithiasis (common bile duct stones; ~70% of cases), benign postoperative or inflammatory biliary strictures, indwelling biliary stent occlusion, or malignant obstruction (pancreatic head adenocarcinoma, cholangiocarcinoma, ampullary cancer);

Bacterial Proliferation within Stagnant Bile : Ascending migration of enteric microorganisms from the duodenum through the sphincter of Oddi.

The Mechanism of Septic Shock : Obstruction causes intrabiliary ductal pressures to rise rapidly above normal physiological limits (>20–25 cm H2O). High hydrostatic pressure breaks down the tight junctions between hepatocytes and biliary canaliculi, precipitating cholo-venous and cholo-lymphatic reflux . Microorganisms and toxic bacterial endotoxins spill directly into the hepatic sinusoids and systemic circulation, triggering overwhelming bacteremia, endotoxemia, and septic shock.

Microbiology of Acute Cholangitis

Infection is typically polymicrobial, reflecting enteric flora:

Gram-Negative Bacilli : Escherichia coli (most common, isolated in 25–50% of bile and blood cultures), Klebsiella pneumoniae (15–20%), Enterobacter species, Pseudomonas aeruginosa ;

Gram-Positive Cocci : Enterococcus faecalis and Enterococcus faecium (10–20%);

Anaerobes : Bacteroides fragilis and Clostridium perfringens (especially in elderly patients or those with previous biliary-enteric bypass surgery).

Clinical Diagnostic Criteria: Charcot's Triad & Reynolds' Pentad ACUTE CHOLANGITIS CLINICAL SPECTRUM

• ┌─────────────────────────────────────────────────────────────────────────────────┐
• │ CHARCOT'S TRIAD (Present in 50-70% of cases) │
• │ 1. High Spiking Fever with Rigors (>38.5°C) │
• │ 2. Right Upper Quadrant (RUQ) Abdominal Pain │
• │ 3. Clinical Jaundice (Total Bilirubin >2.0 mg/dL) │
• └───────────────────────────────────────┬─────────────────────────────────────────┘
• │ Rapid progression if biliary
• │ obstruction remains unrelieved
• ▼
• ┌─────────────────────────────────────────────────────────────────────────────────┐
• │ REYNOLDS' PENTAD (Indicates Toxic Suppurative Cholangitis; Mortality >50%) │
• │ • Charcot's Triad (Fever + RUQ Pain + Jaundice) │
• │ PLUS: │
• │ 4. Systemic Hypotension / Septic Shock (Systolic BP <90 mm Hg) │
• │ 5. Acute Altered Mental Status (Lethargy, Confusion, Delirium) │
• │ │
• │ EMERGENCY PROTOCOL: Aggressive IV Resuscitation + Broad-Spectrum Antibiotics │
• │ + EMERGENT ERCP DECOMPRESSION (<12-24 HOURS) │
• └─────────────────────────────────────────────────────────────────────────────────┘
• Emergency Management of Acute Cholangitis

Hemodynamic Resuscitation : Aggressive IV balanced crystalloid infusions to restore intravascular volume; early initiation of norepinephrine if hypotension persists despite fluid loading.

Immediate Broad-Spectrum Intravenous Antibiotics : Administer within the first hour of triage after obtaining blood cultures:

• Piperacillin-tazobactam (Zosyn) 3.375 g to 4.5 g IV every 6 hours ; OR
• Ceftriaxone 1 g to 2 g IV daily PLUS Metronidazole 500 mg IV every 8 hours ; OR

In patients with severe beta-lactam anaphylaxis or septic shock: Meropenem 1 g IV every 8 hours .

Urgent Biliary Decompression :

Antibiotics cannot penetrate an obstructed, pressurized biliary system; mechanical decompression is the definitive lifesaving therapy.

First-Line Modality : Endoscopic Retrograde Cholangiopancreatography (ERCP) with endoscopic biliary sphincterotomy, stone extraction (balloon or basket), and placement of a biliary drainage stent or nasobiliary catheter.

Timing Guidelines (Tokyo Guidelines TG18) :

Emergent (<12 to 24 Hours) : Mandatory for severe cholangitis manifested by Reynolds' pentad , septic shock, organ dysfunction, or failure to clinically improve within 12 hours of IV antibiotics.

Early (<24 to 48 Hours) : For mild-to-moderate acute cholangitis responding favorably to fluid resuscitation and antibiotics.

Alternative Decompression : If ERCP is technically unfeasible (e.g., prior Roux-en-Y gastric bypass) or unavailable, perform Percutaneous Transhepatic Biliary Drainage (PTBD) under fluoroscopic/ultrasound guidance or emergency open surgical T-tube decompression.

Differential Diagnosis of Severe Jaundice: Pre-Hepatic, Intra-Hepatic & Post-Hepatic

Jaundice (icterus) is the yellow discoloration of the skin, sclerae, and mucous membranes resulting from tissue deposition of bilirubin, clinically detectable when serum total bilirubin exceeds 2.5 to 3.0 mg/dL . Systematic evaluation begins with fractionating serum bilirubin into unconjugated (indirect) and conjugated (direct) components:

Bilirubin Metabolism Essentials

Senescent red blood cells are phagocytosed by reticuloendothelial macrophages in the spleen and liver, cleaving heme into biliverdin and then unconjugated bilirubin .

Unconjugated bilirubin is lipid-soluble and water-insoluble; it circulates in plasma tightly bound to albumin. Because it is bound to albumin, unconjugated bilirubin cannot pass the glomerular filtration barrier and NEVER appears in the urine .

In hepatocytes, uridine diphosphate glucuronosyltransferase (UGT1A1) conjugates bilirubin with glucuronic acid to produce water-soluble conjugated bilirubin .

Conjugated bilirubin is actively secreted across the canalicular membrane into bile (the rate-limiting step) and enters the small intestine.

Colonic bacteria deconjugate bilirubin into colorless urobilinogen :

~80% of urobilinogen is oxidized to stercobilin , the brown pigment that colors feces;

~20% of urobilinogen is reabsorbed into the portal circulation; a small portion (~1–2%) is excreted by the kidneys into urine.

Comprehensive Diagnostic Differential Matrix

Diagnostic Parameter Pre-Hepatic Jaundice (Hemolytic) Intra-Hepatic Jaundice (Hepatocellular) Post-Hepatic Jaundice (Obstructive / Cholestatic)

Primary Pathophysiology Excess bilirubin production exceeding hepatic conjugating capacity Hepatocyte injury, swelling, and impaired canalicular excretion Mechanical physical blockage of extrahepatic biliary outflow

Representative Etiologies Extravascular/intravascular hemolysis (sickle cell crisis, G6PD deficiency, autoimmune hemolytic anemia, microangiopathic hemolytic anemia [TTP/HUS]), ineffective erythropoiesis Acute viral hepatitis (HAV, HBV, HCV, HEV), alcoholic hepatitis, DILI, autoimmune hepatitis, cirrhosis, ischemic hepatitis, genetic transport defects (Gilbert, Crigler-Najjar, Dubin-Johnson) Choledocholithiasis, adenocarcinoma of the pancreatic head, cholangiocarcinoma, ampullary tumors, biliary strictures, acute cholangitis

Bilirubin Fractionation Predominantly Unconjugated (Indirect) ; (Direct fraction <15–20% of total) Mixed Elevation ; (Both conjugated and unconjugated components elevated) Predominantly Conjugated (Direct) ; ( Direct fraction >50% of total )

Urine Color & Dipstick Normal Amber Color ;; Urine dipstick is NEGATIVE for bilirubin (unconjugated is water-insoluble); urine urobilinogen is elevated Dark Tea-Colored / Amber ;; Urine dipstick is POSITIVE for bilirubin (conjugated bilirubin is water-soluble); urine urobilinogen normal or elevated Dark Tea-Colored / Beer-Brown with persistent yellow foam;; Urine dipstick STRONGLY POSITIVE for bilirubin ; urine urobilinogen is ABSENT

Stool Color Normal brown or dark brown (increased stercobilin excretion) Normal or mildly pale Acholic (Pale, Clay-Colored, Putty-Like) due to complete absence of stercobilin pigment

Transaminases (AST & ALT) Normal Markedly Elevated (>1,000 IU/L in viral, toxic, or ischemic liver injury; AST:ALT >2:1 in alcoholic liver disease) Normal or mildly to moderately elevated (early acute obstruction may cause transient spike)

Alkaline Phosphatase & GGT Normal Mild to moderate elevation (<2–3x upper limit of normal) Markedly Elevated (typically >3–5x upper limit of normal ; reflects bile duct epithelial synthesis)

Associated Clinical Hallmarks Elevated LDH, low/undetectable haptoglobin, reticulocytosis, peripheral smear schistocytes/spherocytes; splenomegaly Hepatic encephalopathy, coagulopathy (elevated PT/INR), spider angiomas, palmar erythema, tender hepatomegaly Severe generalized pruritus (bile salt deposition in skin); Courvoisier sign (painless palpable gallbladder in obstructive jaundice indicates pancreatic head cancer)

Loading diagram... Emergency Diagnostic Pathway for Severe Jaundice and Biliary Emergencies